Par Drugs And Chemicals Limited · NSE:PAR
Par Drugs And Chemicals — Q4 FY23 Earnings Presentation
16 slides from Par Drugs And Chemicals's earnings presentation, Jun 1, 2023
Slide 1: Investors Presentation cover letter to NSE
("Par DRUGS AND CHEMICALS LIMITED Registered Office : 815, Nilamber Triumph, Gotri-Vasna Road, Vadodara - 390 007. Gujarat (INDIA). Ph.: +91 - 265 - 2991021 / 2991022 Email: admin@lpardrugs.com CIN No.: L24117GJ1999PLC035512 www pardrugs com PAR/CS/NSE/2023-24/11 To, Date: 01/06/2023 The Manager Lis
Slide 2: Q4-FY23/FY23 Earnings Presentation
("Par DRUGS AND CHEMICALS LIMITED Q4-FY23/FY23 Earnings Presentation
Slide 3: Company Overview
Company Overview
Slide 4: Company Overview
t Company Overview 3 (~Par DRUGS ANO CHEMICALS LIMITED Operational Revenues (INR Mn) • Promoted by Mr. Falgun Savani and Mr. Jignesh (~Par Savani, Par Drugs and Chemicals Limited (PDCL) was founded in 1982 and is engaged in the development 8 DRUGS AND CHEMICALS LIMITED and manufacturing of APIs. 376
Slide 5: Key Strengths
4 Key Strengths (~Par DRUGS ANO CHEMICALS LIMITED Diversified Portfolio: The company manufactures the entire range of products in the Antacid segment. The product portfolio presently comprises 15 APIs and 10 Fine Chemicals which are marketed domestically and exported. Global Presence: The Company is
Slide 6: Financial & Operational Highlights
FINANCIAL & OPERATIONAL HIGHLIGHTS
Slide 7: Q4-FY23/FY23 Financial & Operational Highlights
6 Q4-FY23/FY23 Financial & Operational Highlights (~Par Q4-FY23 Financial Highlights Operational Highlights • Overall, sales growth for the quarter was 11% whereas for the Revenue EBITDA EBITDA Margin FY23 sales grew by around 27% INR 245 Mn INR 53 Mn 21.63% • Sales growth in domestic market was 15%
Slide 8: Q4-FY23/FY23 Financial Overview
Q4-FY23/FY23 Financial Overview
Slide 9: Quarterly Income Statement (IND-AS)
8 Quarterly Income Statement (IND-AS) (~Par Income Statement (INR Mn) Q4-FY23 Q4-FY22 Y-o-Y Q3-FY23 Q-o-Q Income from Operations 245 221 10.9% 229 7.0% Total Expenses 192 176 9.1% 197 (2.5)% EBITDA 53 45 17.8% 32 65.6% EBITDA Margins (%) 21.63% 20.36% 127 Bps 13.97% 766 Bps Finance Cost 0 1 NA 0 NA
Slide 10: Annual Income Statement (IND-AS)
9 Annual Income Statement (IND-AS) (~Par Income Statement (INR Mn) FY23 FY22 Y-o-Y Income from Operations 957 751 27.4% Total Expenses 775 588 31.8% EBITDA 182 163 11.7% EBITDA Margins(%) 19.02% 21.70% (268) Bps Finance Cost 1 5 (80.0)% Depreciation 32 33 (3.0)% Other Income 2 2 NA Profit Before Tax
Slide 11: Historical Income Statement
10 Historical Income Statement (~Par Income Statement (INR Mn) FY20 FY21 FY22 FY23 Income from Operations 558 608 751 957 Total Expenses 464 447 588 775 EBITDA 94 161 163 182 EBITDA Margins (%) 16.85% 26.48% 21.70% 19.02% Finance Cost 8 7 5 1 Depreciation 27 28 33 32 Other Income 1 2 2 2 Profit befo
Slide 12: Balance Sheet
11 Balance Sheet (~Par EQUITIES & LIABILITIES (INR Mn) FY21 FY22 FY23 ASSETS (INR Mn) FY21 FY22 FY23 Shareholder Funds 522 599 712 Non Current Assets 352 351 394 (A) Equity Share Capital 61 123 123 (A) Fixed Assets (B) Reserves & Surplus 461 476 589 (i) Tangible Assets 299 341 385 (ii) Capital work-
Slide 13: Financial Highlights
12 Financial Highlights (~Par Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 182 161 163 116 113 957 92 751 26.48% 94 21.70% 19.08% 558 608 19.02% 16.85% 48 12.25% 11.81% • 8.60% FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 RoCE & RoE
Slide 14: Capital Market Highlights
13 Capital Market Highlights (~Par Stock Market Performance (as on 31st March, 2023) 20% 0% -20% -40% Apr-22 May-22 Jun-22 Jul-22 Aug-22 Sep-22 Oct-22 Nov-22 Dec-22 Jan-23 Feb-23 Mar-23 Par Drugs Nifty 50 52 Price Data (31st March, 2023) INR Shareholding Pattern as on 31st March, 2023 Face Value 10.
Slide 15: Disclaimer
14 Disclaimer (~Par Par Drugs and Chemicals Limited: The above Presentation with slides have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connec
Slide 16: Thank You
Thank You
Par Drugs and Chemicals — Q4 FY23 Earnings Presentation on 6ix